Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650351 · ClinicalTrials.gov registry record · Phase 1
Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT00650351 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 35 participants.
The verdict
NCT00650351, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin extended-release 1000 mg tablets to Bayer's Cipro® XR 1000 mg tablets following a single, oral 1000 mg (1 x 1000 mg) dose administered under fed conditions.
Interventions
- DRUG Ciprofloxacin Extended-Release Tablets 1000 mg
- DRUG Cipro® XR Tablets 1000 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2005-10 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650351
The ClinicalTrials.gov registry entry for NCT00650351 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ciprofloxacin Extended-Release Tablets 1000 mg is the first listed.
NCT00650351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650351 about?
NCT00650351 is a clinical study titled "Food Study of Ciprofloxacin Extended-Release Tablets 1000 mg and Cipro® XR Tablets 1000 mg". The objective of this study was to investigate the bioequivalence of Mylan's ciprofloxacin extended-release 1000 mg tablets to Bayer's Cipro® XR 1000 mg tablets following a single, oral 1000 mg (1 x 1000 mg) dose administered under fed conditions.
What is the current status of trial NCT00650351?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2005-10. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00650351?
The interventions under investigation include: Ciprofloxacin Extended-Release Tablets 1000 mg (DRUG), Cipro® XR Tablets 1000 mg (DRUG).
Who is sponsoring clinical trial NCT00650351?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.